• Clinical Data
  • Subgroup Analyses
  • Efficacy By HER2 Status

TRODELVY 200mg

Clinical Data

Consistent outcomes in post hoc subgroup analyses

TRODELVY helped patients experience improved outcomes vs chemotherapy, regardless of HER2 status*1

OS by HER2 status
OS by HER2 status

Adapted from Hervitz SA, et al. 2022.

*Assessed in patients with and without brain metastases.

ABBREVIATIONS:

2L, second line; CI, confidence interval; DOR, duration of response; HR, hazard ratio; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in-situ hybridisation; NE, not estimable; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

REFERENCES:

  1. Hurvitz SA, et al. Ann Oncol. 2022; 33(3) https://doi.org/10.1016/j.annonc.2022.03.187